PriceTargets.com logo

Allarity Therapeutics - ALLR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.25
  • Forecasted Upside: 697.41%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.16 As of 12/4/2025 05:00 PM ET
▲ +0.07 (6.42%)

This chart shows the closing price for ALLR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allarity Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLR

Analyst Price Target is $9.25
▲ +697.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Allarity Therapeutics in the last 3 months. The average price target is $9.25, with a high forecast of $9.25 and a low forecast of $9.25. The average price target represents a 697.41% upside from the last price of $1.16.

This chart shows the closing price for ALLR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Allarity Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/26/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$9.00 ➝ $9.25
7/28/2025Ascendiant Capital MarketsInitiated CoverageBuy$9.00
8/23/2022LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
5/27/2022LADENBURG THALM/SH SHInitiated CoverageBuy$6,720,000.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Allarity Therapeutics logo
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.16
Low: $1.09
High: $1.18

50 Day Range

MA: $1.36
Low: $0.99
High: $1.76

52 Week Range

Now: $1.16
Low: $0.61
High: $2.35

Volume

170,679 shs

Average Volume

184,016 shs

Market Capitalization

$18.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Allarity Therapeutics?

The following equities research analysts have issued reports on Allarity Therapeutics in the last twelve months: Ascendiant Capital Markets, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ALLR.

What is the current price target for Allarity Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Allarity Therapeutics in the last year. Their average twelve-month price target is $9.25, suggesting a possible upside of 700.9%. Ascendiant Capital Markets has the highest price target set, predicting ALLR will reach $9.25 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $9.25 for Allarity Therapeutics in the next year.
View the latest price targets for ALLR.

What is the current consensus analyst rating for Allarity Therapeutics?

Allarity Therapeutics currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALLR, but not buy more shares or sell existing shares.
View the latest ratings for ALLR.

What other companies compete with Allarity Therapeutics?

Other companies that are similar to Allarity Therapeutics include InflaRx, Vor Biopharma, Assertio, Instil Bio and Acrivon Therapeutics. Learn More about companies similar to Allarity Therapeutics.

How do I contact Allarity Therapeutics' investor relations team?

The company's listed phone number is 401-426-4664 and its investor relations email address is [email protected]. The official website for Allarity Therapeutics is www.allarity.com. Learn More about contacing Allarity Therapeutics investor relations.